Living Cell Technologies Ltd. (LCT) is developing live cell-based therapy products to treat life-threatening human diseases. The company’s most advanced product is for treatment of type 1 insulin dependent diabetes. For patients unable to produce their own insulin, the company implants microencapsulated porcine islet cells so that near-normal blood glucose levels may be achieved at significantly reduced levels of insulin administration. LCT’s approach enables healthy living cells to be injected into patients to replace damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection.

LCT’s Lead Product DiabeCell®

• In phase I/IIa clinical trials for type 1 insulin dependent diabetes
• Insulin-producing porcine islet cells within micro-capsules placed into abdomen using a laparoscopic procedure
• Targeted to patients showing poor control of blood glucose
• Proprietary micro-encapsulation technology
• No immunosuppressive drugs required or used
• 14 patients in clinical trials during 2007 and 2008

DiabeCell® Phase I/IIa Clinical Trials

Russia (in progress)
Protocol: 2 implants per patient, each containing 5,000 islet equivalents (“IEQs”)
No. Patients: 6
Cost: Local partner to cover clinical costs
Monitoring: 2 years

New Zealand (to begin 2008)
Protocol: 1 implant per patient (10,000 to 15,000 IEQs)
No. Patients: 8
Cost: NZ$750,000 (partly covered by NZ grants)
Monitoring: 3 years